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Abstract Sonichedgehog(Shh)signalingiscriticalduring
development and its aberration is common across the spec-
trum of human malignancies. In the cerebellum, excessive
activity of the Shh signaling pathway is associated with the
devastating pediatric brain tumor medulloblastoma. We
previously demonstrated that exaggerated de novo lipid
synthesis is a hallmark of Shh-driven medulloblastoma and
that hedgehog signaling inactivates the Rb/E2F tumor
suppressor complex to promote lipogenesis. Indeed, such
Shh-mediated metabolic reprogramming fuels tumor
progression,inanE2F1-andFASN-dependentmanner.Here,
weshowthatthenutrientsensorPPARcisakeycomponentof
the Shh metabolic network, particularly its regulation of gly-
colysis. Our data show that in primary cerebellar granule
neuralprecursors(CGNPs),proposedmedulloblastomacells-
of-origin, Shh stimulation elicits a marked induction of
PPARc alongside major glycolytic markers. This is also
documented in the actively proliferating Shh-responsive
CGNPsinthedevelopingcerebellum,andPPARcexpression
is strikingly elevated in Shh-driven medulloblastoma in vivo.
Importantly, pharmacological blockade of PPARc and/or Rb
inactivation inhibits CGNP proliferation, drives medullo-
blastomacelldeathandextendssurvivalofmedulloblastoma-
bearing animals in vivo. This coupling of mitogenic Shh
signaling to a major nutrient sensor and metabolic transcrip-
tionalregulatordeﬁneanovelmechanismthroughwhichShh
signaling engages the nutrient sensing machinery in brain
cancer, controls the cell cycle, and regulates the glycolytic
index.ThisalsorevealsadominantroleofShhintheetiology
of glucose metabolism in medulloblastoma and underscores
the function of the Shh ? E2F1 ? PPARc axis in altering
substrateutilizationpatternsinbraincancersinfavoroftumor
growth. These ﬁndings emphasize the value of PPARc
downstreamofShhasaglobaltherapeutictargetinhedgehog-
dependent and/or Rb-inactivated tumors.
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Introduction
Medulloblastomas (MBs) remain the leading cause of death
from solid cancers in children [30]. These predominantly
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DOI 10.1007/s00401-012-0968-6pediatric tumors of cerebellar origin present in infants,
children, and to a lesser extent in the adult population.
Concordantly, MBs are associated with aberrations in sig-
naling cascades critical for brain development, organ
patterning, and cell-fate determination like those controlled
by the Wnt (WNT) or the hedgehog (HH) pathway. As high
as 30 % of total human MBs bear evidence of aberrant
hedgehog pathway activation. In this context, loss of func-
tion mutations in Patched (Ptch) or activating mutations in
Smoothened (Smo), both trans-membrane proteins and
essential components of Shh signaling, have been identiﬁed
in human medulloblastomas [32, 34, 37, 48, 49]. Mutations
in cytoplasmic components of the hedgehog pathway such
as Suppressor of Fused (SuFu) have also been described
[42]. Importantly, ectopic activation of Shh signaling [35,
36], constitutive activation of Smo itself [14, 15], or Ptch
loss-of-heterozygosity [10] are all sufﬁcient, independently,
to drive medulloblastoma formation in vivo. Consistently,
global inhibition of the Shh pathway at the level of its
receptors, while transiently beneﬁcial in MB patients,
remains confounded by a rapid development of drug resis-
tance, a trait also conserved in hedgehog-associated tumor-
bearing mice [50]. Understanding the complexity of Shh
signaling and the corresponding oncogenic network down-
stream of hedgehog is as such critical for developing
effective and speciﬁc nodes for therapeutic manipulation.
In a recent study, we have demonstrated that hedgehog-
driven MBsare distinguishedby adramatic accumulationof
neutral lipids, underscoring these tumors’ metabolic, mark-
edlylipogenic nature[2].Suchlipogenic features aresimilar
to those described in gliomas with EGF receptor mutations
[11] or a number of other human malignancies including
cancer of the breast, lung, and prostate [25]. Importantly, we
demonstrated mechanistically that the effect of Shh on lip-
ogenic metabolism proceeds through a multi-step program
involvingtheinactivationofthetumorsuppressorRbandthe
induction of its negative target E2F1, a key transcriptional
regulatorofproliferationnetworks[16,27,47].Indeed,Shh-
dependent induction of E2F1 promotes de novo lipid syn-
thesis,induces thekeyenzyme FattyAcidsynthase(FASN),
and primes the lipogenic machinery for a bioenergetics
environmentconducivetorapidproliferation.ImpairingE2F
activity and/or targeting de novo lipid synthesis with phar-
macological means produced effective, reproducible
therapeuticoutcomesinMBs-bearinganimalsinvivo.These
non-invasive approaches are especially promising for cur-
rent MB treatments that damage the still-developing brain
and result in catastrophic life-long side effects [31]. It will
be insightful to decipher the key components regulating
the metabolic machinery, in particular, those promoting the
acquisition of permissive substrate utilization patterns
that fuel disease progression and enable malignant
transformation.
It is widely established that adaptations to perceived
stress conditions are hallmarks of proper functioning in
systemic physiology. In fact, reciprocity in coordinated
pathways of glucose and lipid metabolism and ﬂexible
metabolic shifts are common with dietary ﬂux conditions
including starvation, fasting or postprandial states [39–41].
Such exquisite capacity for nutrient sensing is attributed,
broadly speaking, to a complex web of signaling events.
This includes (i) intracellular messengers like cAMP and
associated kinases, (ii) mitochondrial enzymes responsive
to acute changes in biochemical ratios such acetyl-CoA/
CoA and NADH/NAD? ratios, (iii) hormones that recruit
speciﬁc substrate receptors like Glut4, and/or (iv) tran-
scription factors that could alters metabolic patterns and
substrate utilization at multiple, programmatic levels. A
particular class of transcription factors with such capacity
for reprogramming cellular responses and dictating nutrient
sensing and signaling events are the fatty-acid activated
peroxisome proliferator-activated receptors (PPARs).
PPARs can elicit chronic, sustainable metabolic shifts
through their transcriptional effects on metabolic enzyme
gene expression. It is established that PPARc activation
confers signiﬁcant beneﬁt and ameliorate insulin sensitivity
in vivo and ex vivo.
Here, we demonstrate the existence of a novel
mechanism connecting Shh signaling to the PPARc tran-
scriptional machinery in neural precursors and in Shh-
driven medulloblastoma. We show that Shh recruits the
steroid nuclear receptor PPARc, a key element in the
nutrient sensing network, to reprogram cellular metabolism
including the regulation of glycolysis proper. Indeed, Shh-
dependent control of PPARc dramatically activates the
glycolytic modulators Glut4, hexokinase II (HKII) and
pyruvate kinase M2 (PKM2), and promote glucose uptake
in tumors in vivo. Importantly, the mechanism linking Shh
to PPARc and its aforementioned targets requires E2F1 in
vivo and ex vivo. In addition, this process is fully revers-
ible with antagonizing PPARc, an event that remarkably
blunts tumor proliferation and extends survival of animals
with medulloblastoma in vivo. In short, ﬁndings of this
study provide critical insights into how vital and inter-
locked metabolic networks are altered or co-opted in Shh-
driven MBs. The data also underscore the signiﬁcant role
of PPARc downstream of Shh in dictating modes of sub-
strate utilization and deﬁning metabolic patterns in these
tumors, and possibly other hedgehog-associated cancers.
Given the fundamental role for PPARc in nutrient sensing
and the integration of dietary signals on the one hand and
Shh functions in a myriad of biological activities like
proliferation and self-renewal on the other hand, such link
highlights the interplay between cell cycle regulators and
the fuel processing machinery. Furthermore, these results
are equally relevant to the pathophysiology of chronic
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123diseases where glucose metabolism is dysregulated,
particularly where sonic hedgehog activities are also
implicated [21, 22]. Finally, considering the central role of
the Rb-E2F complex in survival and proliferation and the
widespread Rb pathway mutations found in human cancers,
our ﬁndings could assist in better deﬁning the etiology of
tumor metabolism, in particular the perplexing phenotype
of aerobic glycolysis and the lack of efﬁcient mitochondrial
oxidation of glucose despite the ostensible need for ATP in
hyperproliferative cells. The requirement for E2F1 in Shh-
regulated PPARc dependent-glycolysis, as demonstrated,
highlights its engagement in metabolic core ﬂuxes and
underscores the critical role for the Rb/E2F complex in




Wild type C57-BL6 mice and NeuroD2-SmoA1 mice
bearing tumors were administered 10 % dimethyl sulfoxide
(DMSO, control), olomoucine (Calbiochem) at 6 mg/kg
daily or GW9662 (Cayman Chemicals) at 10 mg/kg daily
by intraperitoneal (i.p.) injection. Wild-type C57/BL6
mice, NeuroD2-SmoA1 mice, and E2F1-null mice were
obtained from Jackson Laboratory (Bar Harbor, ME, USA)
and typically were 4–5 months of age when demonstrating
the signs of a tumor (ataxia, etc.).
Cell culture
Cerebellar granule neural precursor cultures were gener-
ated as previously described in detail [19]. The cell culture
media consisted of DMEM-F12 (Gibco, Grand Island, NY)
and 19 dilutions of N2 supplement (as 1009 from Gibco),
Penicillin Streptomycin (1009 from Gibco) and potassium
chloride (2.5 M is a 1009 stock). P4 and P5 wild type C57/
BL6 pups were killed and the cerebellum extracted and
placed into 19 Hanks buffered saline solution (HBSS)
(Gibco) with 6 gm/L of glucose at a pH of 7.4. The HBSS
was aspirated under a tissue hood and trypsin (Gibco) was
added with 1 mg/ml of DNAse. The trypsin was then
inactivated with the media containing 10 % FCS and the
cerebella titurated twice. Following a 5 min spin at
1,500 rpm, the pellet was resuspended in 10 % FCS media.
Cells were then plated on polyornithine-coated six well
plates at a concentration of 3 million cells/mL in 1 mL of
the 10 % FCS media for 6–12 h. The media were then
replaced with FCS free media and given their treatments
and incubated for 24 h before protein lysis. Where indi-
cated Shh (R&D Systems, Minneapolis, MN, USA) was
used at a concentration of 3 lg/ml, cyclopamine (R&D
Systems) was used at 1 lg/ml and GW9662 (Cayman
Chemical, Ann Arbor, MI, USA) was used at 50 or
100 nM.
Western blotting
Protein extracts were prepared as previously described
[20]. A total of 40 lg of murine cerebellum, medullo-
blastoma, or CGNP protein extract were run on 8–12 %
SDS–polyacrylamide gels and transferred to a PVDF
membrane (Millipore, Billerica, MA, USA). The blots were
blocked and incubated with primary antibodies in 5 % milk
in Tris-buffered saline-Tween (TBS-T) overnight in 4 C.
Blots were washed three times and incubated with sec-
ondary antibodies in 5 % milk in TBS-T for 2 h in room
temperature. After washing, the signals were developed
using the enhanced chemiluminescence method (GE
Healthcare, Piscataway, NJ, USA) and the membranes
were exposed to Kodak Biomax ﬁlm. Primary antibodies
were: E2F1 (Cell Signaling, Danvers, MA, USA), PPARc
(E-8; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
FASN (Cell Signaling), Hexokinase I (Cell Signaling),
Hexokinase II (Cell Signaling), Glut4 (Cell Signaling),
PKM2 (Cell Signaling), Cyclin D2 (M-20; Santa Cruz) and
b-tubulin (Sigma). Horseradish peroxidase-conjugated
secondary antibodies were: goat anti-rabbit IgG (H–L;
Thermo Scientiﬁc, Rockford, IL, USA) and donkey anti-
mouse IgG (H–L; Jackson Immuno-Research, West Grove,
PA, USA). Primary antibodies were diluted to 1:1000 for
incubation in 5 % milk in TBS-T with the exception of
b-tubulin, whichwas1:5,000whilethesecondaryantibodies
were at 1:10,000 as recommended by their manufacturers.
Lentivirus production and infection
E2F1 shRNA and scrambled control lentivirus constructs
were obtained from The RNAi Consortium (Sigma,
St Louis MO). Each construct was transfected into the
Pzp53med cell line, which was derived from a medullo-
blastoma arising in a Ptc
?/-/p53
-/- mouse [1], and
western blotting was used to determine which shRNAs
effectively and speciﬁcally targeted E2F1. These constructs
were used to prepare lentiviruses. 293T cells grown in
10 % FBS Dulbecco’s modiﬁed Eagle’s medium (Gibco)
were transfected with E2F1 or scrambled control shRNA
lentiviral vectors and MISSION lentiviral packaging mix
(Sigma) using Fugene 6 in serum-free OPTI-MEM medium
(Invitrogen, Carlsbad, CA, USA). Lentiviral supernatants
were collected 48-h post-transfection and ﬁltered through a
0.45 l ﬁlter, then pooled. For infection, Shh-treated
CGNPs were exposed to the lentiviral supernatant for 4 h.
Control scrambled shRNA lentivirus constructs were used
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effects or non-speciﬁc results because of the process of
virus infection. The lentiviruses were aspirated and
replaced with serum-free CGNP medium (above) contain-
ing Shh. The cells were lysed 48-h post-infection.
Immunostaining
Tissues were ﬁxed in 4 % para-formaldehyde and parafﬁn-
embedded as previously described [3]. After dehydration
steps and sectioning, tissue slides were washed with 19
phosphate buffered saline (PBS) and permeabilized in 1 %
TritonX-100 for 5 min. Slides werethen blocked in 5 % goat
serum in PBS-Tween (19 PBS and 0.1 % TritonX-100) for
1 h in room temperature, washed once with 19 PBS, and
incubatedwithprimaryantibodyin2.5 %goatserum(inPBS-
Tween)overnightat4 C.Theywerewashedthreetimeswith
19 PBS and incubated with secondary antibody for 2 h at
room temperature, then washed and mounted in 40-6-diami-
dino-2-phenylindole-containing mounting medium (Vector
Labs, Burlingame, CA, USA).Primary antibodiesused were:
E2F1 (H-137; Santa Cruz), PPARc (E-8; Santa Cruz), FASN
(CellSignaling,DanversMA),HexokinaseI(CellSignaling),
HexokinaseII(CellSignaling),Glut4(CellSignaling),PKM2
(Cell Signaling), P-Histone H3 (Cell Signaling), and Ki67
(VectorLabs,BurlingameCA).Secondaryﬂuorescent-tagged
antibodies were: Alexa Fluor goat anti-rabbit 488/594
(Invitrogen, Carlsbad, CA) and Alexa Fluor goat anti-mouse
488/594 (Invitrogen).
Image capturing
Immunostaining performed on tissue sections was visual-
ized using a Leica DM5000B microscope and images were
captured with Leica FW400 software (Leica Microsystems,
Bannockburn, IL, USA).
Oil Red O staining
Oil Red O staining of neutral lipids in NeuroD2-SmoA1
medulloblastoma frozen sections was performed by the
histology core in the Department of Pathology and Labo-
ratory Medicine in the Hospital for Special Surgery and by
the microcytometry core facility at Memorial Sloan–Ket-
tering Cancer Center according to established protocols.
PET scanning
For ﬂuorine-18 ﬂuoro-deoxyglucose (FDG) studies using
the Focus 120 microPET small-animal PET scanner
(Concorde Microsystems, Knoxville, TN), animals were
fasted for 6 h prior to injection of the radiotracer; access to
water was permitted. Mice were bolus injected via lateral
tail vein with 300 mCi of the PET radiotracer FDG in
*200 ml of normal saline. At *45-min post-injection, the
mouse was ﬁrst anesthetized by inhalation of a 2 % iso-
ﬂuorane/oxygen gas mixture (ﬂow rate of 2 L/min.) and
placed on the scanner bed in the prone position. The
acquisition is set up for *5 min using a photopeak energy
window of 350–750 keV, and a coincidence timing win-
dow of 6 nsec—and launched using the microPET’s
microPET Manager
TM computer software. Data are
acquired in list mode. The resulting data are sorted into 2D
histograms by Fourier re-binning and transverse images are
reconstructed by ﬁltered back-projection (FBP) into a 3D
imaging matrix using the system Nyquist frequency as the
cut-off. The image data are normalized to correct for non-
uniformity of response of the microPET, dead-time count
losses, positron branching ratio, and physical decay to the
time of injection, attenuation, scatter, or partial-volume
averaging corrections are generally not applied. An
empirically determined system calibration factor (in units
of mCi/mL/cps/voxel) for mice is used to convert voxel
count rates to activity concentrations, and the resulting
image data are then normalized to the administered activity
to parameterize images in terms of percent of the injected
doses per gram (%ID/gm). Manually drawn 2D regions-of-
interest (ROIs) or 3D volumes-of-interest (VOIs) are used
to determined the mean and maximum %ID/g (decay cor-
rected to the time of injection) in tumors and various
organs using ASIPro VM
TM computer software (Concorde
Microsystems).
Cell viability
Cell viability was determined with the cell Titer Glo assay
(Promega, Madison, WI) which utilizes luminescent
reagents reacting with ATP yielding a quantitative
expression of living cells in the sample expressed as a
relative luminescence between samples. This luminescence
was measured with the Glo Max Multi ? (Promega) plate
reader. Statistical analysis was accomplished with SAS
software package (SAS Inst. Inc., N.C., USA). Signiﬁcant
differences between mean were determined by ANOVA
procedure test and a P value of\0.05 was considered to be
statistically signiﬁcant. The results are expressed as the
mean ± SD from quadruplicate test data.
Results
Marked deregulation of PPARc in Shh-driven mouse
medulloblastomas
We have previously reported that the subclass of medul-
loblastomas resulting from aberrant activation of Shh
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novo fatty acid synthesis, as determined by staining for
neutral lipids (Fig. 1a, top left, Oil Red O staining), com-
pared to the adjacent non-tumorigenic cerebellar tissue
(bottom left). This exaggerated lipogenesis is associated
with high levels of proliferation as indicated by Ki67
immunoﬂuorescence, and increased cdk activity, leading to
Rb inactivation and induction of E2F1 (Fig. 1a, b). Indeed,
Fig. 1 Shh-induced mouse medulloblastomas have robust lipogene-
sis, increased levels of E2F1 and PPARc and cell proliferation.
a Triglyceride accumulation was analyzed in a NeuroD2-SmoA1
medulloblastoma using Oil Red O staining; neutral lipids appear as
red droplets. NeuroD2-SmoA1 medulloblastoma (top row) and
adjacent non-tumorous cerebellum (bottom row) were subjected to
immunoﬂuorescence analyses for E2F1, PPARc, and the proliferation
marker Ki67. Primary and secondary antibodies were used at
concentrations of 1:100. Leftmost panel shows hematoxylin and
eosin staining (H&E) staining of the tumor and cerebellar molecular
layer (mol) and inner granule layer (IGL). The non-tumorous
cerebellum immunoﬂuorescence focuses on the boundary between
the IGL and molecular layer demonstrated in the H&E staining.
Magniﬁcation: 91.25 (leftmost panel), 940 (other images). Bars
16 lM. Panels demonstrate the typical outcome from 5 different
tumor and adjoining cerebellum specimens all parafﬁn embedded,
sectioned, and subjected to immunoﬂuorescence for the aforemen-
tioned antibodies. Additionally, the Oil red oil represents a typical
outcome based on the staining of frozen sections from 5 different
specimens. b Protein lysates were prepared from NeuroD2-SmoA1
medulloblastoma and normal cerebellum adjacent to the tumor, and
then analyzed by western blotting for PPARc, lipogenic marker
(FASN) and proliferation markers (E2F1 and cyclin D2). 40 lg
protein/lane was loaded. Data presented are typical for all 5 sets of
tumor and cerebellum samples that were studied. c Western blot
analysis of proteins regulating proliferation andlipogenesis in adjacent
non-tumor cerebellum or medulloblastomas from NeuroD2-SmoA1
mice treated with DMSO (-) or cdk inhibitor olomoucine (?). The
results shown represent a typical outcome amongst the control and
experimental groups of mice
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required for expression of the key lipogenic enzymes
including fatty acid synthase (FASN) and acetyl CoA
carboxylase (ACC), and that abrogation of E2F1 activity in
vivo results in impaired lipogenesis in tumors. This ﬁrmly
linked E2F1 activity downstream of Shh to de novo lipid
synthesis in medulloblastoma and their proposed cells-of-
origins.
PPARc is a pivotal transcription factor that is triggered
by fatty acid ligands and a key regulator of lipogenesis.
Here, using immunostaining and blotting techniques in
mouse NeuroD2-SmoA1 medulloblastomas, we detected
very robust levels of PPARc in the tumors as opposed to
the adjacent non-tumor cerebellar tissues (Fig. 1a, b). We
next examined whether in medulloblastomas expression of
PPARc, like that of FASN, requires E2F1 activity. PPARc
has been reported to be transcriptionally controlled by
E2F1 in adipocytes [7]. We treated medulloblastoma-
bearing mice with the cdk inhibitor olomoucine (6 mg/kg)
for 10 days. As we have previously reported, this treatment
regimen markedly prolongs survival of tumor-bearing mice
and is associated with reduced E2F1 and FASN expression
(Fig. 1c) and with diminished proliferation in the tumors,
as indicated by reduced levels of cyclin D2 (Fig. 1c).
Indeed, olomoucine treatment resulted in a striking
reduction of PPARc levels in the NeuroD2-SmoA1
medulloblastomas (Fig. 1c). These results suggest that
PPARc lies downstream of the Shh ? E2F1 axis in Shh-
driven medulloblastomas and further, that investigating
pathways downstream of PPARc could lead to a better
insight into the biology of medulloblastoma and their
cancer associated metabolic patterns.
Glycolytic enzymes are elevated in NeuroD2-SmoA1
medulloblastomas
Substrate utilization pathways are functionally intertwined.
Cells in anabolic tissues have a large capacity to generate
anew and store fats from excessive glucose inﬂux. We have
shown that Shh-driven medulloblastomas and their pro-
posed cells-of-origin, cerebellar granule neuron precursors
(CGNPs), exhibit high levels of lipogenesis, and here we
report that these tumors feature increased PPARc. In order
to determine whether glycolysis is increased in NeuroD2-
SmoA1 medulloblastomas, we carried out immunostaining
and western blot analysis of medulloblastomas and adja-
cent, non-tumorous cerebellum. As shown in Fig. 2a, b, the
medulloblastomas are marked by a robust accumulation of
many key glycolytic enzymes, including hexokinase II
(HKII), pyruvate kinase M2 (PKM2), and glucose trans-
porter type 4 (Glut4), which control glucose transport,
especially into muscle and adipocytes in response to insulin
stimulation. Notably such patterns appear to be speciﬁc to
HKII as hexokinase I (HKI) levels were higher in normal
cerebellar tissue than in the medulloblastomas.
We next asked whether the expression of these glyco-
lytic enzymes, like that of lipogenic markers, is dependent
upon Rb inactivation and E2F1 activity. To this end we
used western blot analysis of cerebellar tissue and medul-
loblastomas prepared from DMSO- or olomoucine-treated
mice. As shown in Fig. 2c, levels of HKII, PKM2, and
Glut4 were all reduced in olomoucine-treated tumors,
while levels of HKI were up-regulated in the olomoucine-
treated medulloblastomas. These results indicate that the
glycolytic markers are associated with E2F1 activity and
proliferation, and further suggest that HKI plays a role
distinct from glycolysis in differentiated (e.g. normal cer-
ebellum) or non-proliferating tissue (e.g. olomoucine-
treated medulloblastoma).
E2F1 is required for PPARc and the glycolytic markers
expression in neural precursors of the developing
cerebellum
Medulloblastomas associated with increased activity of the
Shh pathway have been proposed to arise from proliferat-
ing neural precursors in the developing cerebellum [6].
During perinatal development, these cells proliferate rap-
idly in the external germinal layer (EGL) response to Shh
secreted from the underlying Purkinje cells (PN) [4, 44,
45]. Upon exiting the cell cycle they migrate inward to the
internal granule layer (IGL), where they undergo terminal
differentiation. Shh-associated medulloblastomas share
many characteristics of these cerebellar granule neuron
precursors (CGNPs), including high expression of N-myc,
microRNA miR 17/92, increased lipogenesis, and as we
previously reported and show again here (Fig. 3a, b) ele-
vated E2F1 [2, 29, 33]. To determine whether increased
glycolysis is also a shared feature of Shh-associated
medulloblastomas and CGNPs, and whether this is, like
lipogenesis, an E2F1-dependent event, we carried out
immunoﬂuorescence and western blot analysis of wild-type
and E2F1-null mouse cerebella at postnatal day 7 (PN7),
when CGNP proliferation is at its peak.
As shown in Fig. 3a (bottom panels) and in Fig. 3b,
PPARc is found in the EGL, as are HKII, PKM2, and
Glut4. We also observed some expression of Glut4 in the
IGL. In contrast, HKI was absent from the EGL and was
highly expressed in the IGL, where differentiating CGNPs
are found. Ablation of E2F1 resulted in loss of expression
of PPARc, HKII, PKM2, and Glut4, but did not affect
levels of HKI. These results suggest that in the developing
cerebellum, as in medulloblastoma, PPARc and glycolytic
markers lie downstream of Sonic hedgehog and E2F1.
We next asked whether CGNPs carry out glycolysis in
vitro, and whether acute manipulation of E2F1 abrogates
592 Acta Neuropathol (2012) 123:587–600
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cultures of CGNPs from PN 4/5 neonatal mice. These cells
are grown in the absence of serum; addition of exogenous
Shh to their medium promotes ongoing proliferation, while
in its absence the cells leave the cell cycle and differentiate
as they would in vivo. We infected Shh-treated CGNPs
with lentiviruses carrying a control, scrambled short hair-
pin RNA (shRNA) sequence or a shRNA sequence
targeting E2F1 for knock-down. As shown in Fig. 3c and
as previously reported, these lentiviruses effectively
knocked down E2F1, while infection with the control
shRNA had no effect on E2F1 levels. In the presence of
Fig. 2 Shh-induced mouse medulloblastomas have high levels of
glycolytic markers of hexokinase II, pyruvate kinase M2, and glucose
transporter-4. a NeuroD2-SmoA1 medulloblastoma (top row) and
adjacent non-tumor cerebellum (bottom row) were subjected to
immunoﬂuorescence analyses for glycolysis (HKI, HKII, Glut4, and
PKM2). Leftmost panel shows hematoxylin and eosin staining (H&E)
staining of the tumor and cerebellar molecular layer (mol) and inner
granule layer (IGL). Magniﬁcation: 91.25 (leftmost panel), 940
(other images). Bars 16 lM. Results shown are typical for the 5
different tumor and adjoining cerebellum samples used for immuno-
ﬂuorescence in this study. b Protein lysates were prepared from
NeuroD2-SmoA1 medulloblastoma and normal cerebellum adjacent
to the tumor, and then analyzed by western blotting for glycolysis.
40 lg protein/lane was loaded. The data shown were repeated with
multiple sets of tumor and cerebellum from different NeuroD2-
SmoA1 mice exhibiting tumors. c Western blot analysis of proteins
regulating glycolysis in adjacent non-tumor cerebellum or medullo-
blastomas from NeuroD2-SmoA1 mice treated with DMSO (-)o r
cdk inhibitor olomoucine (?). The same protein lysates from Fig. 1c
were blotted for glycolytic markers and this is a typical outcome of
those blots
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PKM2, and Glut4, consistent with our observations in vivo.
Levels of HKI were unaffected by the presence of Shh.
Infection with the scrambled shRNA results in a slight
reduction of PPARc levels but has no effect on levels of the
glycolytic markers. In contrast, E2F1 knock-down effec-
tively abrogated expression of PPARc and the associated
glycolytic markers. Taken together, the results of our in
vivo analysis and in vitro manipulation of E2F1 indicate
that in Shh-associated mouse medulloblastomas and in
proliferating CGNPs, glycolysis is elevated in an E2F1-
dependent manner and its regulation functionally lie
downstream of PPARc.
PPARc activity is required for the expression
of glycolytic markers in CGNPs
CGNPs require Shh pathway activity for proliferation as
well as for E2F1 expression. To establish that PPARc and
glycolysis are regulated by Shh upstream of E2F1, we
cultured CGNPs in the presence of Shh or in the presence
of Shh and cyclopamine, which inhibits Smoothened and
blocks Shh signaling. As we have shown previously,
cyclopamine treatment blunts the accumulation of E2F1
and FASN, and reduced proliferation as determined by
cyclin D2 levels (Fig. 4a). Exposure to cyclopamine had no
effect on HKI. However, in the presence of cyclopamine
Fig. 3 Loss of E2F1 in mice ablates PPARc, and key markers of de
novo lipogenesis, glycolysis, and cell proliferation. a PN 7 sagittal
sections of wild-type (bottom row) and E2F1-null (top row) cerebella
were immunostained for the glycolysis-related proteins Glut4, muscle
pyruvate kinase 2 (PKM2), hexokinase 1 and 2 (HKI; HKII) as well
as PPARc, and E2F1 with the proliferation marker phospho-histone
H3. First column panel shows cerebellar inner granule layer (IGL),
Purkinje cells (PC), and external granule layer (EGL). Magniﬁcation:
940. Bars 32 lM. These slides are indicative of several specimens
from the wildtype and E2F null groups that were analyzed with IF.
b Cerebella were collected from wild-type or E2F1-null PN 5 pups,
then analyzed by western blotting for levels of E2F1, PPARc,
glycolysis proteins (HKI, HKII, PKM2, and Glut4), the lipogenic
marker fatty acid synthase (FASN), and proliferation marker cyclin
D2. Results are typical of several sets of protein lysates that were
collected. c Western blot analysis of E2F1, PPARc, glycolysis (HKI,
HKII, PKM2, Glut4) and proliferation marker cyclin D2 in CGNPs
treated with DMSO vehicle, Shh or Shh in the presence of lentiviruses
carrying shRNAs targeting E2F1 or a scrambled control shRNA virus
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123levels of PPARc, HKII, PKM2, and Glut4 were strongly
reduced, consistent with Shh signaling being required for
E2F1 activation and induction of glycolysis, and indicating
that glycolysis is a property associated with CGNP
proliferation.
Thus far, our results indicate a requirement for E2F1
in the regulation of PPARc and the enzymes promoting
glycolysis. As shown in Fig. 3, PPARc and glycolytic
enzymes lie downstream of E2F1. We wished to determine
whether the activity of PPARc is required for glycolytic
marker up-regulation in CGNPs. It is known that treatment
of cells with PPARc agonists such as rosiglitazone is
associated with induction of glycolytic enzymes including
Glut4 [8], although the precise mechanism through which
this takes place is unknown. We carried out dose–response
studies with the PPARc-speciﬁc inhibitor GW9662, which
has been used in vitro and in vivo to inhibit PPARc and
displays no activity towards other PPAR family members
[23, 28]. As shown in Fig. 4b, treatment of CGNPs with 50
or 100 nM GW-9662 resulted in loss of detectable PPARc,
which was remarkably associated with reduced HKII,
PKM2, and Glut4. Importantly, GW9662 treatment had no
effect on HKI and also did not reduce levels of FASN,
indicating that although both FASN and PPARc lie
downstream of E2F1, PPARc and FASN are regulated
independently. Notably, GW9662 treatment also reduced
CGNP proliferation as indicated by diminished cyclin D2
levels. Thus, PPARc activity is required for glycolysis and
ongoing cell division in CGNPs.
Inhibition of PPARc impairs glycolysis
in medulloblastoma and prolongs survival
of tumor-bearing mice
Our data in CGNPs show that PPARc is associated with a
proliferative state, and that PPARc positively regulates
glycolytic markers. Many tumor cells are known to exhibit
high levels of glycolysis, and NeuroD2-SmoA1 medullo-
blastomas are consistently highly proliferative. We wished
to determine whether PPARc inhibition could impair
Fig. 4 Glycolysis in CGNPs is
Shh- and PPARc-dependent.
a CGNP cultures were prepared
for western blot analysis from
PN 4/5 mice and incubated with
vehicle (Veh), Shh (3 lg/ml)
and/or Smoothened inhibitor
cyclopamine (10 lg/ml). The
lysates were blotted for the
glycolytic and proliferative
proteins. The presented work
was repeated with several sets
of CGNP lysates from PN 4/5
mice. b CGNP cultures were
prepared for western blot
analysis from PN 4/5 mice and
incubated with vehicle (Veh),
Shh (3 lg/ml) and/or PPARc
antagonist GW9662 in
increasing doses of 0, 50, and
100 nM
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123glycolysis and affect proliferation in these tumors. We
treated medulloblastoma-bearing NeuroD2-SmoA1 mice
with GW9662 or its vehicle DMSO for up to 10 days,
then harvested the tumors for western blot and
immunoﬂuorescence analysis. As shown in Fig. 5a,
GW9662 treatment had no impact on the level of E2F1 or
FASN,butsharplyreducedPPARcproteinlevels(Fig. 5a,b),
consistent with PPARc lying downstream of E2F1 and in a
Fig. 5 Treatment of medulloblastoma-bearing mice with PPARc
antagonist GW9662 impairs glycolysis in tumor in vivo. a Western
blot analysis for E2F1, PPARc, glycolysis (HKI, HKII, PKM2, and
Glut4),lipidsynthesis(FASN)andproliferation(cyclinD2)insamples
of adjacent cerebella and medulloblastomas from vehicle (DMSO)-
treated(-)orGW9662-treated (?)mice.Theresultsshownaretypical
for several control and experimental sets of mice. b Immunostaining in
adjacent cerebellum and medulloblastomas in vehicle- or GW9662-
treated mice. Slides from the tissue of several untreated and treated
NeuroD2-SmoA mice exhibiting medulloblastomas were analyzed and
the presented results were typical. Magniﬁcation, 940. Bars 16 lM.
cEffectsofincreasingdosesofthePPARcantagonistGW9662(0,0.01,
0.02, 0.05, 0.07, 0.1 lM) for 24 h on pzp53med cell viability as
determined by cell Titer-Glo assay, a bioluminescent analysis based on
thepresenceofATP.Eachbarinthebioluminescencegraphrepresents
the average of separate quadruplicate determinations with error bars
showing the standard deviation of the mean. Bars not sharing common
letter are signiﬁcantly different at P\0.05
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123parallel pathway to FASN. GW9662 treatment also
reduced levels of glycolytic markers and cyclin D2 protein,
but had no effect on HKI, in keeping with our in vitro
results in CGNPs. When tested in the pzp53 MB cell line,
GW9662 treatment was very effective in killing cancer
cells in a dose-dependent manner (Fig. 5c), as show by a
luminescence viability assay (Cell Titer-Glo).
Using FDG-PET analysis, we observed a striking
reduction in glucose uptake in GW9662-treated mice
(Fig. 6a). This correlates with a functional effect of PPARc
inhibition on de novo lipid synthesis (Fig. 6b). Finally, we
assayed the effects of GW9662 treatment on survival
of NeuroD2-SmoA1 medulloblastoma-bearing mice. As
shown in Fig. 6c, from the time of tumor onset as deter-
mined by appearance of detectable symptoms such as head
tilt and altered gait and conﬁrmed by magnetic resonance
imaging, the average length of survival of NeuroD2-SmoA1
animals treated with DMSO (N = 15) was approximately a
week. In contrast, GW9662-treated mice (N = 6) lived for
up to 16 days after tumor onset, a signiﬁcant increase in
survival. These striking results suggest a therapeutic
potential for PPARc inhibition in treating Shh-driven
medulloblastomas.
Discussion
Cross talk between independent yet intertwined signaling
pathways of metabolism and cancer is currently the topic of
increasing scrutiny. We reported earlier a direct transcrip-
tional link between the Rb/E2F tumor suppressor complex
and PDK4 [17], a critical nutrient sensor and a regulator of
mitochondrial glucose oxidation. In more recent work, we
demonstrated that excessive mitogenic signaling by Shh, a
driver of medulloblastoma, engages the Rb/E2F tumor
suppressor complex, activates the key enzyme fatty acid
synthase (FASN) and drives lipogenesis through a novel,
E2F1-regulated process [2]. FASN has also been linked to
survival in glioma cells with activating EGFR mutations
[11, 12] and other tumors [25]. Many transformed cells
also exhibit reliance on glutaminolysis [5, 43], a process
associated with the activity of the myc oncogene [9, 46].
In addition, expression of key tumor suppressors such as
p53, PTEN and LKB1 has been reported to inﬂuence
important regulators of cellular metabolism [18]. Indeed,
many signaling pathways implicated in routine surveillance
themselves go awry across the spectrum of human diseases.
Loss of metabolic inﬂexibility for instance is a pathological
feature in disorders like diabetic cardiomyopathy as well as
in certain cancers, where tumor cells’ addiction to de novo
lipid synthesis for instance appears to be a deﬁning feature
for proliferation and survival [2, 24].
In this study, we show that in medulloblastoma and
CGNPs, the Shh pathway is coupled—through E2F1—to
the steroid receptor PPARc and the control of glycolysis, a
vital cellular process. This coupling underscores the broad
inﬂuence of the hedgehog-regulated metabolic network. It
is signiﬁcant given the role of PPARc as a modulator of
cellular homeostasis as well as a therapeutic target in many
chronic diseases [26]. Indeed, PPARc agonists are rou-
tinely used for the treatment of patients with diabetes or
hyperglycemia and it is established that activation of
PPARc ameliorates insulin sensitivity in vivo and ex vivo.
Nonetheless, the ﬁndings of this study reveal that
Fig. 6 Treatment of medulloblastoma-bearing mice with PPARc
antagonist GW9662 prolongs survival and reduces glucose uptake in
vivo. a FDG-PET scan of medulloblastoma-bearing NeuroD2-SmoA1
mouse before and after treatment with the PPARc antagonist
GW9662 (10 mg/kg, intraperitoneal injection daily over the 8-study
day period). b A representative Oil red O staining of medulloblastoma
sections from an untreated mouse (day 0) and a counterpart treated
with GW9662 for 8 days. c Kaplan–Meyer survival curve of
NeuroD2-SmoA1 medulloblastoma-bearing mice in days commenc-
ing with initiation of treatment with DMSO or GW9662.;
*P value\0.0001, Mantel–Cox test analysis). Magniﬁcation, 940.
Bars 16 lM
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123antagonizing, not stimulating, PPARc would have a prac-
tical therapeutic use in MBs. Indeed, inhibiting PPARc was
markedly beneﬁcial in counteracting hyperproliferation,
reducing tumor burden, and extending the survival of Shh-
driven MBs in mice (Fig. 6). Of note, when examined for
their PPARc expression using tissue microarrays, marked
PPARc staining was detected in [50 % of the Shh sub-
group (Supplementary data). Intriguingly high PPARc
staining was also present in other groups and prevalent in
Group D samples. While more elaborate analysis (includ-
ing demographic, gender, survival) in larger cohorts is
needed to understand the role and function of PPARc in
human tumors, deregulation of this pathway appears to be
widespread in human MB.
The aforementioned role for the E2F1 ? PPARc axis as
a potent effector of hedgehog signaling in modulating the
glycolytic index has also numerous implications. In addi-
tion to presenting a viable therapeutic avenue in this
pediatric brain tumor, it helps explain tumor etiologies
associated with hedgehog and/or Rb/E2F deregulation.
Elevated glucose uptake and hexokinase II activity have
been characteristic features correlated with poor prognosis
in a wide spectrum of malignancies. These features are
routinely exploited in diagnostic imaging techniques like
ﬂuorodeoxyglucose (FDG)-positron emission tomography
[13]. Yet, a sizable number of human cancers are also FDG-
negative and a gradation of glycolic indices is reported
within many tumor types that may or may not reﬂect spe-
ciﬁc lesions. Some positive regulators of cell proliferation
are associated with reduced hexokinase activities and
diminished glycolysis. For instance, antisense-mediated
cyclin D1 down-modulation has been shown to upregulate
glycolysis in vivo, by releasing hexokinase II from inhibi-
tion [38]. These contradictions perhaps reﬂect the
intricacies underlying the cancer-associated metabolic
networks and their confounding heterogeneity. In medul-
loblastoma, a unique, albeit more deﬁned, metabolic pattern
controlled by Shh is beginning to emerge: The striking
accumulation of lipid droplets we describe earlier ([2] and
Fig. 1a), is matched by the equally striking glycolytic index
and conﬁrmed by elevated FDG-PET activity. This phe-
notype is consistent with substrate utilization patterns in
highly anabolic tissues where excessive glucose uptake is
routed to fat production and excessive lipogenesis. More-
over, this particular substrate utilization pattern in shh-
driven MBs unravels a new circuitry coupling hedgehog
signaling directly to glucose uptake. At the heart of this
process is the Rb/E2F complex, itself the target of growth
factors and external trophic signals and a tumor suppressor
broadly inactivated in human cancers. Our work identiﬁed
the (Shh a Rb a E2F1 ? PPAR) axis as a functional
metabolic driver of medulloblastoma tumor formation and
the core of its nutrient sensing network coupling external
dietary conditions to the metabolic adaptation of the cellular
milieu, including the regulation of the glycolic index. We
note that in CGNPs, the mere incubation of primary cells
with Shh markedly triggers Glut4—a glucose transporter
typically induced with insulin stimulation. As such, glucose
utilization in neural precursors could be primarily a Shh-
regulated event, irrespective of hormonal status. Indeed, our
data implicate this E2F1-dependent glycolytic process as a
systematic, distinctly cell-autonomous process that is medi-
ated by PPARc but triggered by Shh in medulloblastoma.
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